Derren Nathan

Derren Nathan

Head of Equity Research

Derren leads our Equity Research team with more than 15 years of experience in his field. Derren enjoys exploring the complex pharmaceutical sector and presenting share ideas for retail investors. He focuses on identifying exceptional companies poised for long-term success through outstanding customer propositions, translating into potential market-beating growth or sustainable dividends.

Covers

Share research and insight

Share research and insight

Contact for press

Latest content from Derren

August 2026

Next week on the stock market

7th August 2026

Eli Lilly (Q2 Results): revenue beat, outlook upgraded

6th August 2026

Diageo (FY Results): sales down, profit beat

6th August 2026

Tritax Big Box (HY Results): good performance, new funds raised

6th August 2026

Novo Nordisk (Q2 Results): GLP-1 momentum drives an upgrade

5th August 2026

Disney (Q3 Results): profit beat, buybacks raised

5th August 2026

Next (Q2 Trading Statement): strong sales, outlook upgraded

5th August 2026

Glencore (HY Results): marketing cashes in on volatility

5th August 2026

BP (Q2 Results): strong quarter, guidance mixed

4th August 2026

Smith & Nephew (HY Results): revenue growth slows, guidance downgraded

4th August 2026

Cameco (Q2 Results): profit slips, production guidance unchanged

3rd August 2026

July 2026

Mastercard (Q2 Results): momentum building

Next week on the stock market

Anglo American (HY Results): copper drives a beat

Haleon (HY Results): steady growth, outlook unchanged

Shell (Q2 Results): billion-dollar beat

British American Tobacco (HY Results): in-line, guidance reaffirmed

Visa (Q3 Results): beat and a raise

Rio Tinto (HY Results): metal prices boost profits

Croda International (HY Results): as expected, guidance unchanged

PayPal (Q2 Results): as expected, strategy in focus

GSK (Q2 Results): small beat, refreshed R&D targets

AstraZeneca (Q2 Results): trading and guidance in-line

Next week on the stock market

CVS Group (FY Update): growth fails to impress

Mitchells & Butlers (Q3 Update): weak quarter, full-year still on track

Investing in climate resilience – 3 opportunities in 3 key sectors

J D Wetherspoon (Trading Update): another profit warning

Intuitive Surgical (Q2 results): solid beat but guidance disappoints

Next week on the stock market

PayPal (Bid Speculation): press report points to $53bn offer

Next week on the stock market

Healthcare share sector view – performance, drivers and opportunities for investors

easyJet (Announcement): progress on bid talks

ITV (Announcement): sale of Media & Entertainment arm

Next week on the stock market

5 shares to watch 2026 – mid-year review

June 2026

BT (Announcement): forming a joint venture with Verizon

easyJet (Announcement): further takeover proposal rejected

Carnival (Q2 Results): good quarter, disappointing guidance

How to use HL's share research

Next week on the stock market

Whitbread (Q1 Trading Update): sales gather pace through first quarter

UK mergers and acquisitions – 3 companies growing through bolt-on acquisitions

Share ideas for investing spare cash or a windfall

GSK (Announcement): acquisition of late-stage biotech

Next week on the stock market

British American Tobacco (Trading Update): soft guidance

May 2026

Next week on the stock market

3 healthcare stocks that could strengthen portfolio resilience in uncertain markets

CVS Group (Announcement): refinancing and share buy back

Mitchells & Butlers (HY results): results in-line, sales growth slowing

Anglo American (Announcement): disposal of steelmaking coal unit

Alibaba (Q4 Results): cashflow under pressure

Imperial Brands (HY Results): profit flat, guidance in-tact

Shell (Q1 Results): strong quarter, buyback trimmed

Novo Nordisk (Q1 Results): volumes building, guidance improved

Smith & Nephew (Q1 Trading Update): $0.5bn buyback, guidance unchanged

J D Wetherspoon (Q3 Update): sales slow, profit pressured

Cameco (Q1 Results ): encouraging start, guidance unchanged

PayPal (Q1 Results): profitability under pressure

Next week on the stock market

April 2026

Whitbread (FY Results): results in-line, guidance disappoints

30th April 2026

Eli Lilly (Q1 Results): beat and a raise

30th April 2026

Mastercard (Q1 Results): revenue and cost guidance raised

30th April 2026

GSK (Q1 Results): strong start, no upgrade

29th April 2026

AstraZeneca (Q1 Results): steady progress

29th April 2026

Haleon (Q1 Results): in-line, no change to guidance

29th April 2026

Visa (Q2 Results): revenue and profit beat

29th April 2026

BP (Q1 results): oil trading drives profit beat

28th April 2026

Shell (Announcement): $16.4bn agreement to buy ARC Resources

27th April 2026

Intuitive Surgical (Q1 results): beat and an upgrade

22nd April 2026

Croda (Trading update): slow start, guidance unchanged

22nd April 2026

Next week on the stock market

17th April 2026

Imperial Brands (Trading Update): full-year guidance intact

14th April 2026

New tax year: Share ideas

Energy infrastructure shares – 3 investment ideas for the long term

5 shares to watch 2026 – how are they performing?

March 2026

CVS Group (Announcement): CEO retirement

30th March 2026

Carnival (Q1 Results): profits rise, guidance dropped

27th March 2026

CVS Group (Announcement): CMA final decision as expected

24th March 2026

Next week on the stock market

20th March 2026

Share sector review – energy

20th March 2026

J D Wetherspoon (HY Results): Profit under pressure

20th March 2026

Alibaba (Q3 Results): cloud shines, core business under pressure

19th March 2026

The 3 new names on our share research watchlist

18th March 2026

BHP (Announcement): CEO succession confirmed

18th March 2026

Next week on the stock market

13th March 2026

Digging deep into mining

10th March 2026

Smith & Nephew (FY results): strong growth, margin outlook disappoints

February 2026

CVS Group (HY results): guidance firm, UK market soft

26th February 2026

Haleon (FY results): sales miss, profit beat

25th February 2026

Croda International (FY Results): small beat, outlook in line

24th February 2026

Novo Nordisk (Announcement): CagriSema trial disappoints

23rd February 2026

Next week on the stock market

13th February 2026

Cameco (Q4 Results): production down but profit up

13th February 2026

British American Tobacco (FY Results): in-line, guidance unchanged

12th February 2026

BP (Q4 results): profit in-line, buyback scrapped

10th February 2026

AstraZeneca (Q4 Results): steady progress

10th February 2026

Next week on the stock market

6th February 2026

Social handles

CV

Head of Equity Research

Hargreaves Lansdown

July 2022 - Present

Head of Research

Hybridian LLP

July 2018 - July 2022 • 4 yrs 1 mo

Investment research

Hybridian LLP

Apr 2014 - July 2022 • 8 yrs 4 mos

In the press

Press articles quoting or featuring our experts and spokespeople. Hargreaves Lansdown is not responsible for these articles’ content and accuracy and may not share the views of the author or publication listed below.

dailymail.co.uk

Chancellor Jeremy Hunt's plan to sell off NatWest shares 'could cost taxpayers £28bn'

morningstar.com

Traders boost bets on mid-2024 rate cut by Bank of England as U.K. jobs market cools

thisismoney.co.uk

Analysts eye more M&A for Britain's hospitality sector